Over the past three decades, several paradigm-shifting therapeutics have been developed for the treatment of cancer, including immune checkpoint inhibitors (ICIs), BRAF and MEK targeted therapies, and cancer vaccines [1]. The gene discussed is MAP2K7; the disease is cancer.